You are here

Tyrosine Kinase Inhibitor Lenvatinib Shows Promise in Melanoma Patients

Lenvatinib/dacarbazine combo more effective than dacarbazine alone in phase II trial (June 10)

The results from a phase II proof-of-concept study indicate that lenvatinib (Eisai Company), an investigational vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI), may have therapeutic effects in melanoma patients.

The randomized open-label study compared lenvatinib plus dacarbazine (one of the standard first-line treatment agents in patients with melanoma) with dacarbazine alone in patients with stage IV chemotherapy-naïve melanoma. The study cohort included patients with BRAF wild-type disease.

The results demonstrated a statistically significant 2.7-fold increase in progression-free survival (PFS) in patients treated with the combination of lenvatinib and dacarbazine versus dacarbazine alone (median PFS: 19.1 weeks vs. 7.0 weeks, respectively; P = 0.0033). In addition, a statistically significant 3.9-fold increase in PFS was observed in a subgroup of patients with BRAF wild-type melanoma treated with the combination of lenvatinib and dacarbazine versus dacarbazine alone (median PFS: 23.9 weeks vs. 6.1 weeks, respectively; P = 0.0306).

Preparations are under way for further studies of lenvatinib in melanoma, with the aim of gaining regulatory approval.

Source: Eisai; June 10, 2013.

Recent Headlines

Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs